Amgen Inc

Stock Chart, Company Information, and Scan Results

$366.14(as of Jul 21, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Amgen Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$366.14
Ticker SymbolAMGN
ExchangeNasdaq
SectorHealthcare
IndustryDrug Manufacturers - General
Employees31,500
CountyUSA
Market Cap$196,545.6M
EBIDTA16,918.0M
10-Day Moving Average363.92
P/E Ratio25.40
20-Day Moving Average360.90
Forward P/E Ratio16.47
50-Day Moving Average346.86
Earnings per Share14.28
200-Day Moving Average336.66
Profit Margin21.11%
RSI55.68
Shares Outstanding539.7M
ATR8.93
52-Week High388.36
Volume1,728,092
52-Week Low264.02
Most Recent Support Level353.95
Book Value9,190.0M
Most Recent Resistance Level378.54
P/B Ratio21.56
Upper Keltner381.00
P/S Ratio5.32
Lower Keltner340.80
Debt-to-Equity Ratio6.24
Next Earnings Date08/04/2026
Cash Surplus-12,917.0M
Next Ex-Dividend DateUnknown

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.